文献类型：期刊文献

英文题名：Genetically engineered bacteria as inflammatory bowel disease therapeutics

作者：Zou, Zhen-Ping[1];Zhang, Xiao-Peng[1];Zhang, Qian[1];Yin, Bin-Cheng[1];Zhou, Ying[1];Ye, Bang-Ce[1]

机构：[1]East China Univ Sci & Technol, Lab Biosyst & Microanal, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China

年份：2024

卷号：4

期号：4

外文期刊名：ENGINEERING MICROBIOLOGY

收录：WOS:【ESCI(收录号:WOS:001532569100003)】；

基金：This work was sponsored by the National Key Research and Development Program of China (2023YFF1204500) , the National Natural Science Foundation of China (22134003) , and China Postdoctoral Science Foundation (2023M741176) .

语种：英文

外文关键词：Genetically engineered bacteria; Inflammatory bowel disease; Bacterial therapeutics

摘要：Inflammatory bowel disease (IBD) is a chronic and recurrent disease caused by immune response disorders that disrupt the intestinal lumen symbiotic ecosystem and dysregulate mucosal immune functions. Current therapies available for IBD primarily focus on symptom management, making early diagnosis and prompt intervention challenging. The development of genetically engineered bacteria using synthetic biology presents a new strategy for addressing these challenges. In this review, we present recent breakthroughs in the field of engineered bacteria for the treatment and detection of IBD and describe how bacteria can be genetically modified to produce therapeutic molecules or execute diagnostic functions. In particular, we discuss the challenges faced in translating live bacterial therapeutics from bacterial design to delivery strategies for further clinical applications.